VPC
JBIO

Vestal Point Capital’s Jade Biosciences JBIO Stock Holding History

Vestal Point Capital’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,429
Closed -$9.05M – 60
2023
Q4 		$9.05M Buy
+11,429
New +$5.82M 0.96% 26

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vestal Point Capital's JBIO Position: Q1 2024 in Review

Vestal Point Capital sold out of Jade Biosciences (JBIO) in Q1 2024, closing a stake of 11,429 shares — an estimated $9.05M sold.

Vestal Point Capital first reported a position in JBIO in Q4 2023 and held it in 1 quarter. The position peaked at $9.05M in Q4 2023. 77 funds tracked by Wall St. Rank hold JBIO as of Q1 2024.

  • Vestal Point Capital reported no remaining Jade Biosciences position as of Q1 2024 after selling out during the quarter.
  • Vestal Point Capital sold 11,429 Jade Biosciences shares in Q1 2024, an estimated $9.05M.
  • Vestal Point Capital first reported a position in Jade Biosciences in Q4 2023 and held it in 1 quarter.
  • Vestal Point Capital's Jade Biosciences position peaked at $9.05M in Q4 2023.
  • 77 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2024.

Based on Vestal Point Capital's 13F filing for Q1 2024, filed 14 May 2024.